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Understanding transcriptional regulation of pancre-
atic development is required to advance current
efforts in developing beta cell replacement therapies
for patients with diabetes. Current knowledge of key
transcriptional regulators has predominantly come
from mouse studies, with rare, naturally occurring
mutations establishing their relevance in man.
This study used a combination of homozygosity
analysis and Sanger sequencing in 37 consanguin-
eous patients with permanent neonatal diabetes to
search for homozygous mutations in 29 transcription
factor genes important for murine pancreatic devel-
opment. We identified homozygous mutations in 7
different genes in 11 unrelated patients and show
that NKX2-2 and MNX1 are etiological genes for
neonatal diabetes, thus confirming their key role in
development of the human pancreas. The similar
phenotype of the patients with recessive mutations
and mice with inactivation of a transcription factor
gene support there being common steps critical for
pancreatic development and validate the use of
rodent models for beta cell development.
INTRODUCTION
Knowledge on transcriptional regulators of pancreatic develop-
ment and beta cell differentiation is essential for the develop-146 Cell Metabolism 19, 146–154, January 7, 2014 ª2014 The Authoment of beta cell replacement therapies for diabetes (Kroon
et al., 2008; Zhou et al., 2008). While major work has been under-
taken in mice, the extent to which murine pancreatic develop-
ment is a good model for man is not fully understood.
Finding inactivating mutations in patients with diabetes can
establish the role of a gene in human pancreatic development
and function. Comparing the human phenotype with mouse
models for the same gene is important, as it validates that the
gene function is similar in man and mouse. Concordant pheno-
types between mouse models with biallelic gene inactivation
and humans with biallelic mutations suggest similar function of
the gene product in rodents and man. For example, biallelic
GCK mutations in humans cause permanent neonatal diabetes
(PNDM), and mice lacking both copies of the gene have
severe hyperglycemia at birth (Njølstad et al., 2001; Terauchi
et al., 1995). Both patients with recessive EIF2AK3 mutations
and the Perk null mouse (Eif2ak3/) develop diabetes due to
destruction of beta cells as a result of endoplasmic reticulum
stress (Dele´pine et al., 2000; Harding et al., 2001; Zhang et al.,
2002)
The correlation in phenotype between knockout mice and
humans with recessive mutations is not always evident. Biallelic
loss-of-function ABCC8mutations are the most common known
cause of hyperinsulinemic hypoglycemia in humans, whereas
ABCC8 null mice maintain euglycemia (Shiota et al., 2002;
Thomas et al., 1995). GLUT2 has been shown to be the primary
glucose transporter and sensor in rodent pancreatic islets,
whereas studies in humans have suggested that GLUT1 plays
an important role in facilitating glucose entry into the developing
beta cell (De Vos et al., 1995; McCulloch et al., 2011). An
example of a difference at the level of the gene structure is the
insulin gene: in humans preproinsulin is encoded by a singlers
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(Ins1 and Ins2).
Studies investigating transcriptional regulation of beta cell
development in mice have, however, been successful in identi-
fying pancreatic transcription factor genes important for human
pancreatic development. Much of the mouse work has involved
the complete or targeted (conditional) knockout of a gene
followed by detailed phenotypic studies during embryonic devel-
opment and, when viable, in the resulting live offspring. To date,
mutations in eight different pancreatic transcription factor genes
(PDX1, PTF1A, GLIS3, PAX6, RFX6, NEUROD1, NEUROG3,
GATA6) have been identified in patients with neonatal diabetes
(Lango Allen et al., 2012; Rubio-Cabezas et al., 2010, 2011; Sell-
ick et al., 2004; Sene´e et al., 2006; Smith et al., 2010; Solomon
et al., 2009; Stoffers et al., 1997). For some transcription factor
genes the genetic etiology in the patients was initially recognized
from the similarity to the mouse phenotype (Rubio-Cabezas
et al., 2010; Stoffers et al., 1997). Mutations causing a pancre-
atic/diabetes phenotype have not been found in man for many
pancreatic transcription factors important for rodent pancreatic
development, but there have been no large, systematic studies
of these genes in appropriate patients to date.
The aim of our study was to perform a comprehensive search
for recessive mutations in genes encoding transcription factors
known to be critical for pancreatic development inmice in a large
collection of PNDM patients born to consanguineous parents.
Patients with consanguineous parents were chosen, as the likeli-
hood of a recessive cause of their PNDM is greatly increased
(Rubio-Cabezas et al., 2009), and all mouse models of transcrip-
tion factors influencing pancreatic development involve biallelic
inactivation. We tested for mutations in homozygous regions
encompassing known transcription factor genes independently
of the clinical features to avoid the possible bias introduced
when clinical features guide candidate gene testing.
RESULTS AND DISCUSSION
We studied 147 patients from consanguineous pedigrees. Muta-
tions in non-transcription factor genes were identified in 110 pro-
bands (75%) (Table 1, Figure S1, and Table S1). Systematic
investigation of 29 transcription factor genes important for
murine pancreatic development identified homozygous muta-
tions in 7 genes in 12 patients from 11 families (30% of the
undiagnosed probands or 7.5% of the entire cohort) (Table 1).
Overall, 106 out of 121 (88%) patients with a known genetic
etiology had homozygous mutations, confirming that neonatal
diabetes in the offspring of consanguineous families is usually
recessive.
Homozygous Mutations in NKX2-2 Cause Neonatal
Diabetes
Homozygous NKX2-2 nonsense or frameshift mutations were
identified in three patients from two families (Table 2). These
mutations are highly likely to be pathogenic, as they are null
mutations. Cosegregation studies were consistent with reces-
sive inheritance (Figure 1A). No heterozygous or homozygous
truncating mutations have been reported in 6,500 individuals
sequenced by the NHLBI Exome Sequencing Project (http://
evs.gs.washington.edu/EVS/). All three patients have severe de-Cellfects in insulin secretion, as shown by intrauterine growth retar-
dation (IUGR) and presentation of diabetes at an early age
without features of pancreatic exocrine dysfunction (Table 2).
This is very similar to mice that are homozygous for a targeted
disruption ofNkx2-2 and die shortly after birth with severe hyper-
glycemia (Briscoe et al., 1999; Sussel et al., 1998) (Table 2). They
have normal exocrine function, lack beta cells, and have fewer
alpha and pancreatic polypeptide cells (Sussel et al., 1998).
The patients with homozygous null mutations in NKX2-2 also
have severe developmental delay, which affects both motor
and intellectual function as well as more specific features, such
as hypotonia, cortical blindness, impaired visual tracking, and
hearing impairment. These are consistent with the severe neuro-
logical features seen in theNkx2-2 knockoutmouse (Table 2) and
Nkx2-2 being essential for hindbrain development, ventral
neuronal patterning, and oligodendrocyte differentiation (Bris-
coe et al., 1999; Qi et al., 2001).
Homozygous Mutations inMNX1 Cause Neonatal
Diabetes
Two probands have homozygous missense mutations in MNX1
(previously described as HLXB9). The p.F248L and p.F272L
missense mutations are highly likely to be pathogenic, as they
cosegregate with neonatal diabetes (Figure 1B), affect highly
conserved residues within the homeodomain (Table 2, Fig-
ure 1C), are not listed in 6,500 individuals sequenced by the
NHLBI Exome Sequencing Project, and in silico analysis pre-
dicted the mutations to be disease causing. Our results are in
line with the recently published paper by Bonnefond et al.
(2013), who independently found the sameMNX1 p.F272Lmuta-
tion in proband 2. Both probands in our study had severe intra-
uterine growth retardation and were diagnosed with diabetes
in infancy without evidence of exocrine pancreatic dysfunction.
This is similar to the Mnx1 null mice that are born smaller than
their wild-type littermates and have small islets and reduced
numbers of beta cells and normal exocrine function (Table 2)
(Harrison et al., 1999). These mice also have dorsal lobe agen-
esis of the pancreas; it is not known if this is a feature of our
two patients, as imaging and post mortem investigations were
not performed. Proband 1 (but not proband 2) had marked ex-
trapancreatic developmental features, including severe neuro-
logical complications and hypoplastic lungs (respiratory failure
caused death at 10 months) (Table 2). In keeping with these
observations,Mnx1 null mice have aberrant motor neuron differ-
entiation but are difficult to study as they die at birth due to res-
piratory paralysis, which probably results from failure in the
development of the phrenic nerve (Thaler et al., 1999). The vari-
ability in phenotype between the two probands could be due to
differences in the severity of their mutations, but further studies
investigating the functional consequences of these missense
mutations are required in order to explore this hypothesis.
Proband 1 also had sacral agenesis and a high imperforate
anus, which are both cardinal features of Currarino syndrome
(OMIM #176450), resulting from heterozygous MNX1 mutations
(Currarino et al., 1981; Ross et al., 1998). Mice homozygous for
a null mutation do not have skeletal defects (Harrison et al.,
1999). Proband 2 and his heterozygous relatives do not have fea-
tures of Currarino syndrome. The highly variable phenotype is
not unexpected, as around 50% of heterozygous carriers areMetabolism 19, 146–154, January 7, 2014 ª2014 The Authors 147
Table 1. Pancreatic Transcription Factor Gene Analysis in Patients with Neonatal Diabetes, Related to Tables S1 and S2
Gene
Diabetes Phenotype
of the Null Mouse
Number of
Homozygous
Regions
in 37 Patients
Mutations
Identified in
PNDM
Patients
Homozygous Region
Coordinates
Homozygous
Mutations Identified
Reference(s) in which
Patient Was Previously
Reported
FOXA1 – 2 0 – – –
FOXA2 embryonic lethal 1 0 – – –
GATA4 embryonic lethal 2 0 – – –
GATA6 embryonic lethal 3 0 – – –
GLIS3 neonatal diabetes 4 2 chr9: 36,587–4,187,290
chr9: 39,094,547–
46,744,084
p.? (c.1.?_388 + ?del)
p.G311fs (c.932 delG)
Dimitri et al., 2011
HES1 pancreatic hypoplasia 2 0 – – –
HHEX pancreatic hypoplasia 1 0 – – –
HNF1B embryonic lethal 1 0 – – –
INSM1 neonatal lethal 2 0 – – –
ISL1 pancreatic hypoplasia 2 0 – – –
MAFA diabetes at 8–12 weeks 0 0 – – –
MAFB neonatal lethal 4 0 – – –
MNX1 pancreatic hypoplasia 10 2 chr7: 147,339,570–
158,659,419
chr7: 155,022,291–
158,811,981
p.F248L (c.744C > G)
p.F272L (c.816C > A)
Bonnefond et al., 2013
NEUROD1 neonatal diabetes 3 1 – p.D122fs (c.364 dupG) Rubio-Cabezas et al.,
2010
NEUROG3 neonatal diabetes 1 0 – – –
NKX2.2 neonatal diabetes 2 2 chr20: 4,435,760–
60,974,283
chr20: 19,494,958–
32,325,488
p.P119fs (c.356 del)
p.R129X (c.385C > T)
–
NKX3.2 4 0 – – –
NKX6.1 reduced insulin secretion 2 0 – – –
NKX6.2 4 0 – – –
ONECUT1 adult-onset diabetes 3 0 – – –
PAX4 neonatal diabetes 1 0 – – –
PAX6 neonatal lethal 0 0 – – –
PDX1 pancreatic agenesis 4 2 chr13: 27,258,487–
42,966,967
chr13: 21,702,312–
43,640426
p.A152G (c.455C > G)
p.R176Q (c.527G > A)
De Franco et al., 2013
PTF1A pancreatic agenesis 8 1 chr10: 14,877,485–
49,578,351
p.? (c.784 + 4A > G) Lango Allen et al., 2012
RBPJ embryonic lethal 2 0 – – –
RBPJL 4 0 – – –
RFX6 neonatal diabetes 5 1 chr6: 109,613,154–
144,987,523
p.S217P (c.649T > C) Smith et al., 2010
SOX17 embryonic lethal 1 0 – – –
SOX9 embryonic lethal 6 0 – – –
Total: 29 – Total: 84 Total: 11 – – –
Transcription factor genes important for murine pancreatic development and the resulting diabetes phenotype in null mice. Genome-wide SNP typing
identified 84 homozygous regions encompassing a transcription factor gene in 30 patients with permanent neonatal diabetes. Using Sanger
sequencing, 11 mutations were detected in 7 of these genes.
Cell Metabolism
NKX2-2 and MNX1 Mutations Cause Neonatal Diabetesclinically asymptomatic (Ko¨chling et al., 2001). As diabetes is not
a feature of Currarino syndrome, it seems likely that a single copy
ofMNX1 is sufficient to maintain normal pancreatic development148 Cell Metabolism 19, 146–154, January 7, 2014 ª2014 The Authoand glucose homeostasis, a hypothesis that is further supported
by the observation that heterozygous mice have a normal
pancreas (Harrison et al., 1999).rs
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Homozygous mutations in five pancreatic transcription factor
genes previously reported to cause PNDM were identified in
seven probands. The phenotype of these patients is similar to
that seen in mice with biallelic inactivation of these genes
(Table 3). Our two patients with GLIS3 mutations, the six previ-
ous cases (Dimitri et al., 2011; Sene´e et al., 2006), and the
Glis3 mouse knockout (Watanabe et al., 2009) all have neonatal
diabetes diagnosed in the first week of life and congenital
hypothyroidism. We identified one patient with a homozygous
NEUROD1mutation. Both this patient and a previously reported
case from a nonconsanguineous pedigree (Rubio-Cabezas
et al., 2010) have neonatal diabetes, neurodevelopmental delay,
cerebellar hypoplasia, and hearing and visual impairment.
The Neurod1 null mouse also has neonatal diabetes and
severe neurological defects, including impaired coordination
and ataxia, cerebellar hypoplasia, sensorineural deafness, and
retinal blindness (Liu et al., 2000; Miyata et al., 1999; Morrow
et al., 1999; Naya et al., 1997; Pennesi et al., 2003). The proband
with a homozygousRFX6mutation was diagnosed with diabetes
at 8 days and had duodenal atresia and gall bladder agenesis.
This is consistent with the previous five cases and the Rfx6
knockout mouse, which has neonatal diabetes and small bowel
atresia (Smith et al., 2010).
Two probands with homozygous PDX1 (previously described
as IPF1) missense mutations had isolated PNDM. In both man
and mouse, the severity of the PDX1 mutation determines the
pancreatic phenotype. Pancreatic agenesis was seen in the
mouse knockout (Jonsson et al., 1994) and in patients with two
copies of a severe mutation (Fajans et al., 2010; Schwitzgebel
et al., 2003; Stoffers et al., 1997, 1998; Thomas et al., 2009). In
mice, hypomorphic mutations are associated with diabetes
without evidence of exocrine deficiency (Oliver-Krasinski et al.,
2009); we and others have shown that patients with less-severe
homozygous missense mutations have neonatal diabetes with
normal or mildly impaired exocrine function (De Franco et al.,
2013; Nicolino et al., 2010).
An intronic PTF1Amutation (c.784 + 4A > G) was identified in a
proband with pancreatic agenesis. This mutation is predicted to
result in an alternative splice donor site (Alamut Interactive
Biosoftware, version 2.1) and the inclusion of an additional 4
bases in themRNA, causing a frameshift and premature termina-
tion codon at residue 271. The pancreatic phenotype is similar to
the three previously reported patients with nonsense or frame-
shift mutations and the Ptf1a null mouse (Al-Shammari et al.,
2011; Krapp et al., 1998; Sellick et al., 2004). Our patient has
mild learning difficulties at 15 years old, which is in contrast to
the other patients who had severe neurological features, causing
death before 4 months of age. These patients and the knockout
mouse had cerebellar aplasia. In a mouse model, reduced Ptf1a
gene dosage results in pancreatic hypoplasia and glucose intol-
erance in a dose-dependent manner (Fukuda et al., 2008). We
hypothesize that the absence of cerebellar agenesis in this
patient may reflect a reduced functional severity of the splicing
mutation compared to previously reported null mutations.
The finding that mutations in NKX2-2 and MNX1 can cause
neonatal diabetes takes the number of genes in which mutations
are known to cause PNDM from 18 to 20, of which 10 encode
pancreatic transcription factors. Unlike previous studies, whichrs
Figure 1. NKX2-2 and MNX1 Mutations in Four Families with Neonatal Diabetes
(A) Partial pedigrees of two families in whichNKX2-2mutations were identified. Below each pedigree is an electropherogram depicting the homozygousmutation
identified in each proband. N/A, not available.
(B) Partial pedigrees of two families with MNX1 mutations. Below each pedigree is an electropherogram depicting the homozygous mutation identified in each
proband.
(C) The highly conserved sequence of the homeobox domain within MNX1 is provided for various species. An arrow points to the residues found to be mutated in
the two probands with permanent neonatal diabetes. See also Figure S1.
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phenotype with the null mouse, our systematic approach guided
by areas of linkage has allowed us to screen all transcription fac-
tor genes independently of clinical features. Our results confirm
that the consequence of inactivation of pancreatic transcription
factor genes in humans is similar to the phenotype observed in
knockout mice. This is in contrast to heterozygous loss-of-
function mutations where differences in phenotype have been
observed. For example, monoallelic mutations in GATA6 or
HNF1B cause pancreatic agenesis with congenital heart defects
or renal cysts with diabetes, respectively, while mice heterozy-
gous for a null mutation in Gata6 or Hnf1b show no obvious
phenotype (Bingham et al., 2001; Haumaitre et al., 2005; Lango
Allen et al., 2012; Morrisey et al., 1998).
There are some limitations to our study. The minimum preva-
lence of transcription factor mutations in our cohort of patients
with consanguineous PNDM was 7.5%, but the true prevalence
may be slightly higher since heterozygous or compound hetero-
zygous mutations would have been missed as a result of the
study design. However, as all of the patients were known to be
consanguineous, the prior probability is that they have reces-
sively inherited disease due to a homozygous mutation. While
the identification of patients with homozygous inactivating muta-
tions in pancreatic transcription factor genes has confirmed theirCellrole in human organogenesis, these findings can only provide
limited information on pancreatic development, as detailed
physiological studies in man are not always possible. This is
especially true for the patients within our cohort with NKX2-2
and MNX1 mutations that are all currently under 13 years of
age and, for those withNKX2-2 mutations, have severe develop-
mental delay, which means that in-depth studies on pancreatic
and neurological function are not possible.
In conclusion, we have shown that mutations in NKX2-2 and
MNX1 cause neonatal diabetes. This confirms a key role for
NKX2-2 and MNX1 in human pancreatic development. Compar-
isons of phenotypes observed in humans andmice with inactiva-
tion of transcription factor genes supports common steps critical
for pancreatic development. This study validates the use of
knockout mice for understanding beta cell development in
humans.
EXPERIMENTAL PROCEDURES
Cohort
We recruited 147 patients from consanguineous pedigrees (parents of the
proband were second cousins or more closely related) who were diagnosed
with permanent diabetes before 6 months of age or were diagnosed with
permanent diabetes before 9 months and had any additional clinical features
that made a diagnosis of type 1 diabetes less likely. Informed consent wasMetabolism 19, 146–154, January 7, 2014 ª2014 The Authors 151
Table 3. A Comparison of the Phenotype Observed in the Patients with Homozygous Mutations in Known Pancreatic Transcription
Factors to the Phenotype Observed in Homozygous Inactivation in Mice
Gene Mutation
Patient Mouse
ReferencesPancreas Additional Features Pancreas Additional Features
GLIS3 c.1.?_388 +
?del1
neonatal
diabetes
renal cystic dysplasia,
congenital hypothyroidism,
hepatic fibrosis
null: neonatal
diabetes
null: neonatal lethality,
polycystic kidney disease,
congenital hypothyroidism
Watanabe et al.,
2009
c.932 delG neonatal
diabetes
multiple small renal cysts,
congenital hypothyroidism,
osteopenia, anemia
NEUROD1 c.364 dupG2 neonatal
diabetes
learning difficulties, severe
cerebellar hypoplasia,
sensorineural deafness,
retinal dystrophy
null: neonatal
diabetes
null: cerebellar hypoplasia,
impaired coordination and
ataxia, impaired hearing
and balance, retinal
degeneration, blindness,
and seizures
Kim et al., 2001; Liu
et al., 2000; Morrow
et al., 1999; Naya
et al., 1997
PDX1 p.A152G3 neonatal
diabetes
none reported null: pancreatic
agenesis
hypomorphic
mutation: neonatal
diabetes
null: abnormal duodenum
and stomach morphology
hypomorphic mutation:
none reported
Jonsson et al., 1994;
Offield et al., 1996;
Oliver-Krasinski et al.,
2009; Stoffers et al.,
1997
p.R176Q3 neonatal
diabetes
none reported
PTF1A c.784 +
4A > G4
pancreatic
agenesis
none reported null: pancreatic
agenesis
hypomorphic
mutation: pancreatic
hypoplasia
null: cerebellar hypoplasia
hypomorphic mutation:
cerebellar hypoplasia
Fukuda et al., 2008;
Hoshino et al., 2005;
Kawaguchi et al.,
2002; Krapp et al.,
1998; Sellick et al.,
2004
RFX6 p.S217P5 neonatal
diabetes
duodenal atresia,
gall bladder agenesis
null: neonatal
diabetes
null: small bowel atresia Smith et al., 2010
Some patients have been reported previously by Dimitri et al. (2011), Rubio-Cabezas et al. (2010), De Franco et al. (2013), Lango Allen et al. (2012), and
Smith et al. (2010).
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approval was received for this study.
Exclusion of Nontranscription Factor Mutations in PNDM
To detect mutations in non-transcription factor genes that cause PNDM,
we used Sanger sequencing (ABCC8, KCNJ11, INS) in all patients, followed
by homozygosity mapping with sequencing of known genes (EIF2AK3,
IER3IP1, GCK, SLC19A2, and SLC2A2) within homozygous regions >3 Mb.
Detecting Mutations of Pancreatic Transcription Factor Genes
Frompublished literature, we identified 29 transcription factor genes crucial for
murine pancreatic development (Seymour and Sander, 2011; Zaret and
Grompe, 2008) (Table 1). We identified homozygous regions through
genome-wide single nucleotide polymorphism (SNP) genotyping and used
Sanger sequencing to detect mutations within homozygous regions encom-
passing these genes.
Genome-wide SNPAnalysis to Localize Etiological Genes by Linkage
Genotyping was undertaken on the Affymetrix 10K, 500K, or v6.0 SNP
chips by Medical Solutions, ALMAC Diagnostics, or AROS Applied Biotech-
nology. Processing of genomic DNA was performed as per the Affymetrix
protocol, and in-house Perl scripts were developed to identify regions of
significant homozygosity (>3 Mb) as previously described (Flanagan et al.,
2011).
Sequencing of Pancreatic Transcription Factor Genes
When a large homozygous region encompassing one of the pancreatic tran-
scription factor genes was identified, the coding regions and intron and
exon boundaries of the gene were sequenced (Table 1, Figure S1, and Tables
S2 and S3). Details of PCR primers and sequencing conditions are available on152 Cell Metabolism 19, 146–154, January 7, 2014 ª2014 The Authorequest. Pathogenicity was assessed on the basis of the characteristics of the
mutation, the conservation of the affected amino acid, the absence from
variant databases (accessed using Alamut v.2 Interactive Biosoftware), and
cosegregation within families.
Patient Phenotype Assessment
For patients with homozygous mutations, their phenotype (both pancreatic
and extrapancreatic) was compared with the phenotype of the knockout
mouse for the same gene.
SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure and three tables and can be
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